Revvity Inc
RVTY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$868.00 | Nkhxkns | Gvhvcwf |
PerkinElmer Raises 2021 Outlook After Strong Q2 and Announces BioLegend Acquisition; Raising FVE
Narrow-moat PerkinElmer reported strong second-quarter results that beat expectations, and management raised its outlook for 2021 again. On recently generated cash flows and strong near- and long-term prospects, we're raising our fair value estimate to $131 per share from $106 previously. Our new fair value incorporates the planned BioLegend acquisition that was also announced July 26 but still remains below market prices.